A phase II clinical trial (NCT01639508) reported that RET-fusion positive lung cancer patients receiving cabozantinib (60mg, p.o. daily) demonstrated partial response (28%; 7/25 patients) and fortifies the notion that RET is actionable in lung cancers (132, 203). The gene discussed is RET; the disease is lung cancer.